Atomoxetine

Starting dose: Paediatric population (6-17 years) <70kg- total daily dose of approximately 0.5 mg/kg.

Paediatric population (6-17 years) >70kg and Adults- 40mg daily in the morning.

The following table is a guide but appropriate dosing should be checked for individual patients.

Dose escalation: Dose increases should be at minimum weekly intervals according to clinical response and tolerability.

Maximum dose: 100mg daily.

• Hypersensitivity to the active substance or to any of the excipients
• During or for 14 days after treatment with an MAO inhibitor. MAOI should not be initiated within 2 weeks after discontinuing atomoxetine.
• Narrow angle glaucoma
• Severe cardiovascular or cerebrovascular disorders. Severe cardiovascular disorders may include severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels). Severe cerebrovascular disorders may include cerebral aneurysm or stroke.
• Phaeochromocytoma or a history of phaeochromocytoma

Very common: Headache, abdominal pain, somnolence, nausea, vomiting, appetite decreased, blood pressure increased, heart rate increased.

Common: Dizziness, insomnia, constipation, fatigue, mood changes including irritability, depression, anxiety.

Uncommon: Suicide related events, aggression, hostility, and emotional lability, tremor, syncope, tachycardia, migraines, QT prolongation, blurred vision

See SPC for full details

Can be stopped abruptly in cases of significant adverse effects as no distinct withdrawal symptoms have been described. Otherwise, can be tapered off over a suitable time period.